MannKind gaps up at open, but trades off earlier highs The shares are up 7.6% at time of writing to $10.76 following an extremely volatile session late Friday afternoon eastern time. At current price resistance is at $10.99 and then at $11.22. Support is at $10.42. JPMorgan remains cautious on the stock, maintaining a $6 price target. Brinson Patrick raised its price target to $15.
MannKind triples production capacity for Afrezza MannKind announced that it has completed the validation of two additional filling lines for the manufacture of Afrezza inhalation powder. Material produced during the validation runs, including the recently approved 12 unit cartridges, will be supplied to Sanofi to support the launch of the new dosage strength, which is expected later this quarter.